Back to Search
Start Over
Liposomal‐encapsulated doxorubicin supercharge‐containing front‐line treatment improves response rates in primary mediastinal large B‐cell lymphoma and mediastinal gray zone lymphoma.
- Source :
- Hematological Oncology; Jan2024, Vol. 42 Issue 1, p1-5, 5p
- Publication Year :
- 2024
-
Abstract
- This article presents the findings of a study on the use of liposomal-encapsulated doxorubicin in the treatment of primary mediastinal large B-cell lymphoma (PMBL) and mediastinal gray zone lymphoma (MGZL). The study examined the efficacy and safety of a new treatment regimen called R-COMP-DIx6, which included a higher dose of the medication. The study found that the treatment resulted in a high rate of complete metabolic response and was well-tolerated with minimal side effects. However, the study had limitations, including a small sample size and a long duration of data collection. Further research is needed to validate these findings in a larger clinical trial. [Extracted from the article]
- Subjects :
- DIFFUSE large B-cell lymphomas
DOXORUBICIN
SPECKLE tracking echocardiography
Subjects
Details
- Language :
- English
- ISSN :
- 02780232
- Volume :
- 42
- Issue :
- 1
- Database :
- Complementary Index
- Journal :
- Hematological Oncology
- Publication Type :
- Academic Journal
- Accession number :
- 175070853
- Full Text :
- https://doi.org/10.1002/hon.3247